Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer

Oncology Letters

Volumn 10, Issue 1, 2015, Pages 51-60

  Wang, Hongmei ^a,b   Li, Yongchun ^c   Yu, Wencheng ^a   Ma, Liqing ^c   Ji, Xia ^c   Xiao, Wei ^b  

^a QINGDAO UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

Lung cancer; RAGE; RAGE polymorphism; Soluble RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; PROTEIN S 100;

ADENOCARCINOMA; ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER INCIDENCE; CANCER STAGING; CONTROLLED STUDY; DNA POLYMORPHISM; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMALL CELL CARCINOMA; SMOKING; SQUAMOUS CELL CARCINOMA; UPREGULATION;

EID: 84929913926     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3200     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Pulford DJ, Falls JG, Killian JK and Jirtle RL: Polymorphisms, genomic imprinting and cancer susceptibility. Mutat Res 436: 59-67, 1999.
3. Galvani E, Peters GJ and Giovannetti E: EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity. Future Oncol 8: 1015-1029, 2012.
4. Habbous S, Pang V, Eng L, et al: p53 Arg72Pro polymorphism, HPV status and initiation, progression and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res 18: 6407-6415, 2012.
5. Herold K, Moser B, Chen Y, Zeng S, Yan SF, Ramasamy R, Emond J, Clynes R and Schmidt AM: Receptor for advanced glycation end products (RAGE) in a dash to the rescue: Inflammatory signals gone awry in the primal response to stress. J Leukoc Biol 82: 204-212, 2007.
6. Brett J, Schmidt AM, Yan SD, et al: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143: 1699-1712, 1993.
7. Bartling B, Hofmann HS, Weigle B, Silber RE and Simm A: Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma. Carcinogenesis 26: 293-301, 2005.
8. Englert JM, Hanford LE, Kaminski N, et al: A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 172: 583-591, 2008.
9. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H and Yasui W: Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 196: 163-170, 2002.
10. Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC and Huang EH: RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum 50: 1230-1240, 2007.
11. Hsieh HL, Schäfer BW, Sasaki N and Heizmann CW: Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 307: 375-381, 2003.
12. Sparvero LJ, Asafu-Adjei D, Kang R, et al: RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 7: 17, 2009.
13. Tesarová P, Kalousová M, Jáchymová M, Mestek O, Petruzelka L and Zima T: Receptor for advanced glycation end products (RAGE) - soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 25: 720-725, 2007.
14. Schenk S, Schraml P, Bendik I and Ludwig CU: A novel polymorphism in the promoter of the RAGE gene is associated with non-small cell lung cancer. Lung Cancer 32: 7-12, 2001.
15. Wang X, Cui E, Zeng H, Hua F, Wang B, Mao W and Feng X: RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC. PLoS ONE 7: e43734, 2012.
16. Mountain CF: A new international staging system for lung cancer. 1986. Chest 136 (Suppl): e25, 2009.
17. World Medical Association: World Medical Association Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed March 11, 2015.
18. Lehr HA, Mankoff DA, Corwin D, et al: Anpplication of photoshop-based image analysis to quantification of hormone receptor expression in breast cancer. J Histochem Cytochem 45: 1559-1565, 1997.
19. Wang Y, Wang H, Piper MG, et al: sRAGE induces human monocyte survival and differentiation. J Immunol 185: 1822-1835, 2010.
20. Beránek M, Kanková K, Kolár P and Znojil V: Polymorphisms in the von Willebrand factor gene are not associated with proliferative retinopathy in non-insulin-dependent diabetes mellitus. Ophthalmic Res 34: 327-330, 2002.
21. Kanková K, Márová I, Záhejský J, Muzík J, Stejskalová A, Znojil V and Vácha J: Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. Metabolism 50: 1152-1160, 2001.
22. Tam XH, Shiu SW, Leng L, Bucala R, Betteridge DJ and Tan KC: Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond) 120: 81-89, 2011.
23. Bopp C, Hofer S, Weitz J, Bierhaus A, Nawroth PP, Martin E, Büchler MW and Weigand MA: sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 147: 79-83, 2008.
24. Liu X, Chen Q, Shi S, Shi Z, Lin R, Tan L, Yu J, Shu Q and Fang X: Plasma sRAGE enables prediction of acute lung injury after cardiac surgery in children. Crit Care 16: R91, 2012.
25. Garber ME, Troyanskaya OG, Schluens K, et al: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98: 13784-13789, 2001.
26. Jabaudon M, Futier E, Roszyk L, et al: Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients. Crit Care Med 39: 480-488, 2011.
27. Piperis M, Provatopoulou X, Sagkriotis A, Kalogera E, Ampatzoglou E, Zografos GC, Athanasiou E and Gounaris A: Effect of breast cancer adjuvant therapies on potential biomarkers of pulmonary inflammation. Anticancer Res 32: 4993-5002, 2012.
28. Fujisawa K, Katakami N, Kaneto H, et al: Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis 227: 425-428, 2013.